Senior Leadership

高层领导

基本信息

项目摘要

PROJ ECT SU M MARY (See Instructions): The Hollings Cancer Center (HCC) is directed by Andrew S. Kraft, MD with the assistance of a senior leadership team, and together they represent the strong functional nexus of this matrix-based Center. The team is comprised of eight associate directors, each of whom has outstanding expertise in their area of responsibility. They are: Anthony J. Alberg, PhD, MPH, Associate Director of Cancer Control; Marvella E. Ford, PhD, Associate Director of Cancer Disparities; Anita L. Harrison, MPA, Associate Director of Administration; Philip H. Howe, PhD, Associate Director of Basic Sciences; Michael B. Lilly, MD, Associate Director of Translational Research; Steven A. Rosenzweig, PhD, Associate Director of Shared Resources; Melanie B. Thomas, MD, Associate Director of Clinical Investigations; Dennis K. Watson, PhD, Associate Director of Education & Training; and Kevin F. Staveley-O'Carroll, MD, PhD, Medical Director of the HCC Clinical Service Line. The HCC senior leadership team meets once a month as a formal Executive Council, one-on-one with the Director at least monthly, and more frequently with each other and the Director in the context of various HCC board/committee meetings. They provide direct counsel and recommendations to the Director based on these interactions. All final authority for decisions on behalf of the HCC resides with the Director. Dr. Kraft has charged the senior leadership with employing consensus-building techniques as they work directly with the program leaders, shared resource directors, and various HCC boards and committees in formulating center-wide priorities, strategies, and allocation of resources. They work together as a team to ensure consistency in the mission, vision, and goals of the Center and develop synergistic interactions among the basic, translational, and clinical elements of the Center. They provide feedback on the growth of the HCC in their area of responsibility, which is particularly important given the rapid growth of the HCC, and evolving research directions at the national level. Based on this, they plan and implement proactive, integrative approaches for development of the research base, resources, and a formal strategic plan. The consistency of vision is particularly important in effectively leveraging all available resources at MUSC and at the state and national levels and engagement of the community in outreach activities.
项目说明玛丽(参见说明): Hollings癌症中心(HCC)由Andrew S. Kraft,MD在高级领导团队的协助下,他们共同代表了这个基于矩阵的中心的强大功能联系。该小组由八名协理主任组成,每名主任都在其职责范围内具有杰出的专门知识。他们是:安东尼J阿尔伯格,博士,公共卫生硕士,癌症控制副主任;福特博士,癌症差异副主任;哈里森,MPA,行政副主任;菲利普H。Howe,PhD,基础科学副主任; Michael B. Lilly,医学博士,转化研究副总监; Steven A. Rosenzweig博士,共享资源副总监; Melanie B。托马斯,医学博士,临床研究副总监; Dennis K.沃森,博士,教育和培训副主任;和凯文F。Staveley-O 'Carroll,MD,PhD,HCC临床服务线的医学总监。合同委员会高级领导小组作为正式的执行理事会每月举行一次会议,至少每月与主任一对一会晤,并在合同委员会各理事会/委员会会议上更频繁地与彼此和主任会晤。他们根据这些互动向主任提供直接咨询意见和建议。代表合同委员会作出决定的最终权力属于主任。 博士卡夫公司要求高级领导层采用建立共识的技术,因为他们直接与项目负责人、共享资源主管和各种HCC董事会和委员会合作,制定中心范围的优先事项、战略和资源分配。他们作为一个团队一起工作,以确保中心的使命、愿景和目标的一致性,并在中心的基础、翻译和临床要素之间建立协同互动。他们提供关于HCC在其职责范围内发展的反馈,鉴于HCC的快速发展以及国家一级不断变化的研究方向,这一点尤为重要。在此基础上,他们计划和实施积极的,综合的方法来发展研究基地,资源和正式的战略计划。愿景的一致性对于有效利用MUSC以及州和国家各级的所有可用资源以及社区参与外联活动尤为重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GUSTAVO WALTER LEONE其他文献

GUSTAVO WALTER LEONE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GUSTAVO WALTER LEONE', 18)}}的其他基金

Leaders of Scientific Research Programs
科研项目带头人
  • 批准号:
    9248281
  • 财政年份:
    2017
  • 资助金额:
    $ 38.45万
  • 项目类别:
CELL EVALUATION & THERAPY
细胞评估
  • 批准号:
    9248291
  • 财政年份:
    2017
  • 资助金额:
    $ 38.45万
  • 项目类别:
Administration
行政
  • 批准号:
    9248296
  • 财政年份:
    2017
  • 资助金额:
    $ 38.45万
  • 项目类别:
LIPIDOMICS SHARED RESOURCE GROUP
脂质组学共享资源组
  • 批准号:
    9248286
  • 财政年份:
    2017
  • 资助金额:
    $ 38.45万
  • 项目类别:
Clinical Trials Office and Data & Safety Monitoring
临床试验办公室和数据
  • 批准号:
    9248289
  • 财政年份:
    2017
  • 资助金额:
    $ 38.45万
  • 项目类别:
BIOREPOSITORY & TISSUE ANALYSIS
生物样本库
  • 批准号:
    9248298
  • 财政年份:
    2017
  • 资助金额:
    $ 38.45万
  • 项目类别:
CANCER CONTROL
癌症控制
  • 批准号:
    9248285
  • 财政年份:
    2017
  • 资助金额:
    $ 38.45万
  • 项目类别:
Planning and Evaluation
规划与评估
  • 批准号:
    9248294
  • 财政年份:
    2017
  • 资助金额:
    $ 38.45万
  • 项目类别:
DEVELOPMENTAL CANCER THERAPEUTICS
发育性癌症治疗
  • 批准号:
    9248284
  • 财政年份:
    2017
  • 资助金额:
    $ 38.45万
  • 项目类别:
Leaders of Scientific Research Programs
科研项目带头人
  • 批准号:
    9454303
  • 财政年份:
  • 资助金额:
    $ 38.45万
  • 项目类别:

相似海外基金

HNDS-R: Connectivity, Inclusiveness, and the Permeability of Basic Science
HNDS-R:基础科学的连通性、包容性和渗透性
  • 批准号:
    2318404
  • 财政年份:
    2023
  • 资助金额:
    $ 38.45万
  • 项目类别:
    Standard Grant
Advancing the basic science of membrane permeability in macrocyclic peptides
推进大环肽膜渗透性的基础科学
  • 批准号:
    10552484
  • 财政年份:
    2023
  • 资助金额:
    $ 38.45万
  • 项目类别:
Computer Vision for Malaria Microscopy: Automated Detection and Classification of Plasmodium for Basic Science and Pre-Clinical Applications
用于疟疾显微镜的计算机视觉:用于基础科学和临床前应用的疟原虫自动检测和分类
  • 批准号:
    10576701
  • 财政年份:
    2023
  • 资助金额:
    $ 38.45万
  • 项目类别:
Bringing together communities and basic science researchers to build stronger relationships
将社区和基础科学研究人员聚集在一起,建立更牢固的关系
  • 批准号:
    480914
  • 财政年份:
    2023
  • 资助金额:
    $ 38.45万
  • 项目类别:
    Miscellaneous Programs
“L-form” bacteria: basic science, antibiotics, evolution and biotechnology
L 型细菌:基础科学、抗生素、进化和生物技术
  • 批准号:
    FL210100071
  • 财政年份:
    2022
  • 资助金额:
    $ 38.45万
  • 项目类别:
    Australian Laureate Fellowships
Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions
早期病变转化和基础科学研究协调和数据管理中心
  • 批准号:
    10517004
  • 财政年份:
    2022
  • 资助金额:
    $ 38.45万
  • 项目类别:
Developing science communication on large scale basic science represented by accelerator science
发展以加速器科学为代表的大规模基础科学科学传播
  • 批准号:
    22K02974
  • 财政年份:
    2022
  • 资助金额:
    $ 38.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
UCSF - UCB TRAC Basic Science CORE
UCSF - UCB TRAC 基础科学核心
  • 批准号:
    10674711
  • 财政年份:
    2022
  • 资助金额:
    $ 38.45万
  • 项目类别:
Basic Science Core - Imaging
基础科学核心 - 成像
  • 批准号:
    10588228
  • 财政年份:
    2022
  • 资助金额:
    $ 38.45万
  • 项目类别:
Basic Science Core - Biosafety & Biocontainment Core (BBC)
基础科学核心 - 生物安全
  • 批准号:
    10431468
  • 财政年份:
    2022
  • 资助金额:
    $ 38.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了